Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer
Jürgen Wolf, Takashi Seto, Ji‐Youn Han et al. · New England Journal of Medicine · 2020
BACKGROUND: amplifications occur in 1 to 6%. Capmatinib, a selective inhibitor of the MET receptor, has shown activity in cancer models with various types of MET activation. METHODS: amplification according to gene copy number in tumor tissue). Patients received capmatinib (400-mg tablet) twice daily. The primary end point was overall response (complete or partial response), and the key secondary end point was response duration; both end points were assessed by an independent review committee whose members were unaware of the cohort assignments. RESULTS: amplification and a gene copy number of 10 or higher, overall response was observed in 29% (95% CI, 19 to 41) of previously treated patients and in 40% (95% CI, 16 to 68) of those who had not received treatment previously. The most frequently reported adverse events were peripheral edema (in 51%) and nausea (in 45%); these events were mostly of grade 1 or 2. CONCLUSIONS: -amplified advanced NSCLC was higher in tumors with a high gene copy number than in those with a low gene copy number. Low-grade peripheral edema and nausea were the main toxic effects. (Funded by Novartis Pharmaceuticals; GEOMETRY mono-1 ClinicalTrials.gov number, NCT02414139.).
Cited by 1,000 works. doi:10.1056/nejmoa2002787 Open-access PDF
Authors
- Jürgen Wolf
- Takashi Seto
- Ji‐Youn Han
- Noemı́ Reguart
- Edward B. Garon
- Harry J.M. Groen
- Daniel S.W. Tan
- Toyoaki Hida
- Maja J.A. de Jonge
- Sergey Orlov
- Egbert Frederik Smit
- Pierre-Jean Souquet
- Johan Vansteenkiste
- Maximilian Johannes Hochmair
- Enriqueta Felip
- Makoto Nishio
- Michael Thomas
- Kadoaki Ohashi
- Ryo Toyozawa
- Tobias Raphael Overbeck
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer